Georgia Made Medical Manufacturing Act Signed Into Law
On Tuesday, May 4th, Governor Kemp signed Senate Bill 6 into law. SB 6 contains language for the Georgia Made Medical Manufacturing Act, which allows for an additional $1250 tax credit for all new jobs engaged with pharmaceutical and medical supply/device manufacturing. Language for the GMMMA was previously included on several pieces of legislation but received final passage on the last day of session on a Conference Committee Report to SB 6. The law will go into effect on July 1, 2021.
This legislation signals the value that Gov. Kemp and the General Assembly place on the important work of the life sciences industry. We thank them for their support and look forward to working with them to expand our industry and its economic impact here in Georgia.
From L to R: Ashley Haltom, Maria Thacker-Goethe, Gov. Brian Kemp, Shay Foley, Karla Kiriako
The post Georgia Made Medical Manufacturing Act Signed Into Law appeared first on Georgia Bio.
New coalition forms to develop a national innovation roadmap to strengthen and extend America’s global leadership in biotechnology
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
